CD274 and non-small cell lung carcinoma: The clinical benefit of PD-1/PD-L1 inhibitors is usually predicted by immunohistochemical determination of PD-L1 expression levels [63]; high expression (> 1 or > 50% in NSCLC) is associated with better response rates [64, 65].